GNPX
Genprex Inc
Halal Rating :
Last Price
$0.72
Last updated:
Market Cap
-
7D Change
-0.97%
1 Year Change
235.97%
Company Overview
Industries
Exchange
Next Earnings Date
Genprex Inc is a clinical-stage gene therapy company focused on developing innovative therapies for patients with cancer and diabetes. Their lead product candidate is REQORSA™ Immunogene Therapy, which is being developed for non-small cell lung cancer (NSCLC). The company utilizes its unique, proprietary platform technologies, including their non-viral ONCOPREX® Nanoparticle Delivery System.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| June 30, 2024 | $-620.0 | $6.52m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Genprex Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.